Medication Comparisons: What the Network Meta-Analyses Say
The comparative evidence on cessation medications, from the Cochrane network meta-analysis tradition.
The main comparisons
- Varenicline vs NRT monotherapy: varenicline generally emerges as the more effective single agent in network meta-analyses (R-008; Cochrane partial-agonists review R-002).
- Varenicline vs bupropion: varenicline generally superior on quit rates (R-002, R-008).
- Cytisine vs NRT: Walker 2014 (R-017) found cytisine noninferior-to-superior at 1 month, with the difference narrowing and becoming non-significant at 6 months — at much lower cost. Cochrane partial-agonists analyses include cytisine (R-002).
- Cytisine vs varenicline: fewer head-to-head trials; both are partial agonists; varenicline has the larger trial base.
- Combination NRT (patch + fast-acting form): more effective than single-form NRT (R-008) — the standard advice in UK services.
- E-cigarettes vs NRT: high-certainty evidence favors nicotine e-cigarettes (R-013) — but see the e-cigarettes controversy for the full picture.
What is genuinely uncertain
- Whether cytisine fully matches varenicline in direct comparison (ongoing trials).
- Optimal duration of treatment.
- Which medication is best for specific subgroups (heavy smokers, psychiatric comorbidity, pregnancy — USPSTF marks pregnancy pharmacotherapy as an I statement).
Reading note
"More effective on average" is not "better for you". Choice involves cost, availability, side-effect profile, prior experience and preference — which is why every medication page here ends with questions for a healthcare professional, and why this platform never ranks medications for individuals.